InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,592.40
(
-0.10%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.10
(
-0.46%
)
Bitcoin
64,117.87
(
1.51%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 88

Wednesday, 04/04/2018 7:29:43 PM

Wednesday, April 04, 2018 7:29:43 PM

Post# of 438
AIMT 's oral peanut allergy treatment will likely be the first choice for ages 4-17

It will also be first to market and enjoy market preference for most adults until and if ANAB's treatment comes to market

FDA approval could come in 2019

Competitor ANAB's treatment targets adults and is 6 years away from coming to market

Competitor DBVT 's patch is best suited for infants and pre-schoolers and has poorer overall efficacy.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up